Identification of canonical NFκB (C-NFκB) pathway in uveal melanoma and their relation with patient outcome.
Immunohistochemistry
Inflammation
NFκB
Uveal melanoma
c-Rel/p50 heterodimer
p65/p50
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
29
01
2019
accepted:
03
05
2019
pubmed:
10
5
2019
medline:
11
3
2020
entrez:
10
5
2019
Statut:
ppublish
Résumé
Inflammation in uveal melanoma (UM) is linked to a bad prognosis. It is rare type of cancer, of which the metastases are usually fatal within a year. Infiltration with an inflammatory infiltrate increases with disease progression but does not seem to inhibit metastasis. The Canonical NFκB (C-NFκB) pathway is known to play a crucial role in tumor inflammation. We therefore, studied the expression of canonical NFκB proteins and their prognostic relevance in UM. Our study evaluated the expression of C-NFκB proteins (p65, p50, and c-Rel) by using immunohistochemistry on sections from 75 formalin-fixed UM. Activation of the NFκB subunit was determined on fresh tumor specimens by measuring the DNA-binding activity in nuclei using an NFκB ELISA assay. Real-time PCR was performed on frozen material on 58 tumors. The presence of native C-NFκB heterodimers (p65/p50 and c-Rel/p50) was confirmed by co-immunoprecipitation followed by Western blotting. We observed a high nuclear immunoreactivity of p65, p50, and c-Rel proteins in 54, 60 and 41% UM cases, respectively. Expression of C-NFκB proteins significantly correlated with parameters which are related to the inflammatory environment of UM. Nuclear immunoreactivity of p65 and p50 was associated with lower patient survival (p = 0.041; p = 0.048) while c-Rel was not. Our finding reveals that C-NFκB proteins expressed are more often in UM with inflammation than those without inflammation. Activation of the canonical NFκB pathway is more frequent in high risk UM patients. These observations might help to understand the behaviour of high risk tumors, with upregulation of C-NFκB proteins contributing to tumor aggressiveness.
Identifiants
pubmed: 31069565
doi: 10.1007/s10585-019-09969-y
pii: 10.1007/s10585-019-09969-y
doi:
Substances chimiques
DNA-Binding Proteins
0
NF-kappa B p50 Subunit
0
Proto-Oncogene Proteins c-rel
0
REL protein, human
0
RELA protein, human
0
Transcription Factor RelA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-290Références
Semin Immunol. 2000 Feb;12(1):85-98
pubmed: 10723801
Cancer. 2000 Dec 1;89(11):2274-81
pubmed: 11147598
Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1414-21
pubmed: 11381040
Nat Rev Cancer. 2002 Apr;2(4):301-10
pubmed: 12001991
Clin Cancer Res. 2004 Apr 1;10(7):2466-72
pubmed: 15073126
Biochem J. 2004 Sep 1;382(Pt 2):393-409
pubmed: 15214841
Nature. 2004 Sep 23;431(7007):461-6
pubmed: 15329734
J Pathol. 2004 Dec;204(5):569-77
pubmed: 15481028
Am J Ophthalmol. 2004 Dec;138(6):936-51
pubmed: 15629284
Ocul Immunol Inflamm. 2005 Feb;13(1):105-10
pubmed: 15835077
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S37-46
pubmed: 16113098
Structure. 2005 Sep;13(9):1365-73
pubmed: 16154093
Nature. 2006 May 25;441(7092):431-6
pubmed: 16724054
Adv Immunol. 2006;90:1-50
pubmed: 16730260
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
Nat Rev Immunol. 2007 Jan;7(1):41-51
pubmed: 17186030
Breast Cancer Res. 2007;9(4):210
pubmed: 17640394
Invest Ophthalmol Vis Sci. 2008 Feb;49(2):505-10
pubmed: 18234992
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):1811-6
pubmed: 19892878
Invest Ophthalmol Vis Sci. 2011 Feb 03;52(2):643-50
pubmed: 20811059
Prog Retin Eye Res. 2011 Mar;30(2):129-46
pubmed: 21129496
Cancer Metastasis Rev. 2011 Mar;30(1):5-12
pubmed: 21249426
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Pathol. 2011 Aug;64(8):695-700
pubmed: 21551466
Nat Immunol. 2011 Jul 19;12(8):715-23
pubmed: 21772280
Eye (Lond). 2013 Feb;27(2):217-23
pubmed: 23238448
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Dis Markers. 2014;2014:494581
pubmed: 24864130
J Cancer Res Ther. 2014 Jul-Sep;10(3):631-5
pubmed: 25313751
JAMA Ophthalmol. 2015 Apr;133(4):376-83
pubmed: 25555246
Indian J Ophthalmol. 2015 Feb;63(2):93-102
pubmed: 25827538
Comp Med. 2015 Apr;65(2):140-3
pubmed: 25926400
Oncotarget. 2015 Sep 15;6(27):23157-80
pubmed: 26324762
PLoS One. 2016 Oct 20;11(10):e0164292
pubmed: 27764126
Oncol Lett. 2017 Oct;14(4):4037-4042
pubmed: 28959363
Clin Transl Oncol. 2018 Dec;20(12):1592-1603
pubmed: 29796997
Mol Cancer Res. 2018 Dec;16(12):1902-1911
pubmed: 30093564
PeerJ. 2018 Sep 13;6:e5563
pubmed: 30225173
Cancer Res. 1997 Jul 15;57(14):3032-9
pubmed: 9230219
Am J Ophthalmol. 1998 Jun;125(6):745-66
pubmed: 9645714
Clin Cancer Res. 1999 Jan;5(1):119-27
pubmed: 9918209